Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

Authors :: Unglaub, Julia M.
Schlenk, Richard F.
Middeke, Jan Moritz
Krause, Stefan W.
Kraus, Sabrina
Einsele, Hermann
Kramer, Michael
Zukunft, Sven
Kauer, Joseph
Renders, Simon
Katelari, Elena
Schliemann, Christoph
Pabst, Caroline
Luft, Thomas
Dreger, Peter
Röllig, Christoph
Bornhäuser, Martin
Müller-Tidow, Carsten
Sauer, Tim
Source :: Blood Advances; 20240101, Issue: Preprints
Publication Year :: 2024
Abstract: •VEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy.•The VEN plus HMA combination allows for a safe and effective bridging to allo-HCT.

Full Text Access

Tools